PGR and cancer: Our study showed varying levels of estrogen and progesterone receptor expression in primary and paired recurrent tumors, supporting the use of early endocrine maintenance therapy in the first-line setting, following standard chemotherapy for estrogen and/or progesterone receptor positive cancer.